Authors

Fast Is Not the Same as Trustworthy: The Data Standing Behind an Effective AI Answer

Exploring the emergence of agentic ecosystems in transforming data accessibility and ensuring reliable answers reach the people making decisions while there is still a choice to make.

Realtime Electronic Data Capture at Investigator Sites: Laboratory Data and Beyond

The End of the Rebate Era? What HR Leaders and Pharmacy Consultants Need to Know About Biosimilars

As the availability and utilization of ultra-high-cost, long-term specialty products such as GLP-1s and cell and gene therapies grows, HR decision-makers and pharmacy consultants must embrace a more value-oriented mindset where they can.

2025 Pharma Forecast: Four Pivotal Trends Revolutionizing Market Access Strategies

From Infrastructure to Experience: Why Specialty Therapies Are Reshaping How Organizations Think About Patient Support

Specialty therapies now account for more than half of US drug spending. As innovation accelerates, patient support has expanded to include patient services, digital engagement, specialty pharmacy partnerships, reimbursement support, and personalized programs. As treatments become more individualized, patient journeys grow more complex. They require patients to manage treatment schedules, ongoing self-monitoring, caregiver involvement, and multiple transitions while interacting with providers, reimbursement specialists, specialty pharmacies, and clinical educators. The challenge is that patients rarely experience these capabilities one at a time; they experience how those functions come together, or don't, across their journey, which carries meaningful implications for how engagement is designed. Jennifer Wagner, Senior Vice President of Client Solutions at Momentum Life Sciences, examines why the conversation is shifting from building support to designing programs around how patients experience treatment.

From Blockbusters to Black Holes: Pharma Launch Strategy in the Age of Technology and AI

From Dashboards to Decisions: How AI Is Reshaping Pharma Brand Strategy

AI-powered data analytics has evolved from a supporting function into the backbone of modern brand strategy and decision-making.

The performance gaps most fleet programs can’t see

How pharmaceutical and life sciences fleets can uncover hidden operational costs by connecting maintenance, telematics, fuel, routing, and lifecycle decisions

How ClaimGuardRx's Purpose-Built AI Detects and Counters Diversion Tactics

Bryan Dennison breaks down the purpose-built technology behind ClaimGuardRx and how its detect-and-respond design keeps manufacturers ahead of evolving diversion tactics.

The Evolution of Healthcare Communication: Bridging the HCP-Patient Divide

Key trends in healthcare communication to build trust between healthcare providers and their patients.

The AI Force Multiplier: How AI Is Leveling the Playing Field for Small and Mid-Size Biotech

By giving small and mid-size biotechs access to real-world data and advanced analytics once reserved for large pharma, AI platforms are leveling the playing field by enabling lean teams to de-risk clinical strategy, strengthen fundraising narratives, and make faster, more confident decisions across the development lifecycle.

Why Pharma’s Next Communications Model Won’t Be a Cascade

How the proposed lateral network can change the traditional mindset around communications and pharma’s role in today’s new flow of health information.

HEOR: From Proving Product Value to Proving Its Own Worth

The recent shift in Health Economics and Outcomes Research functions across major pharmaceutical companies highlights a lack of understanding of its value.

Strategic advantage: Optichannel engagement drives ROI across the product lifecycle

Your Phase III Clinical Protocol Is Your Initial Product Launch

How demand-driven development will help new products be more successful.

Korea and Australia's P&MA Shift: From Local Launch Opportunities to Regional Blueprint

Recent policy shifts in these two influential health technology assessment markets signal a broader regional move toward faster, more innovation-friendly access frameworks.

Navigating Cross-Border Pharma Deals: Key Trends and Lessons Out of China

The importance of a strategic approach and proper due diligence in unlocking the full potential of these arrangements.

Transforming Life Sciences R&D: The Business Case for AI

Webinar Date/Time: Thu, Aug 14, 2025 3:30 PM EDT

JCA vs. Reality: Europe’s Push for Clinical Harmonization

Europe’s Joint Clinical Assessment promises harmonization, but it introduces a new layer of strategic complexity that manufacturers must navigate at both EU and national levels.

Going Beyond Compliance: Early Adoption of FDA’s Quality Management Maturity Program—and the Practical Considerations for Executives

An examination of proactive preparedness and readiness review for future enrollment in the agency’s QMM program—now in the pilot stage as an effort to incentivize pharma manufacturers to achieve a more mature state of quality culture.

How Agentic AI Is Reshaping the Launch Playbook for Pharma

The agentic model is emerging as a strategic tool to compress analysis timelines, coordinate cross-functional teams and surface competitive intelligence in real time.

Taking Advantage of ‘Hidden Gem’ Talent Hubs

How to optimize a pharma location strategy in unheralded but rich regions for biotech talent around the world.

How QMM Can Help the C-Suite See a $100 Million Problem Early

A passing FDA inspection tells pharma senior leadership very little about whether the next significant revenue vulnerability is already taking shape. But continuous, AI-enabled quality management maturity (QMM) has the potential to do so months before the issue reaches the realm of P&L.

Zeno’s Paradox, Orphan Product Access and the Future of Unmet Need

Unmet need is likely a new battlefield impacting prior authorization.

HEOR: From Proving Product Value to Proving Its Own Worth

The recent shift in Health Economics and Outcomes Research functions across major pharmaceutical companies highlights a lack of understanding of its value.

How to Overcome Supply Chain Constraints and Enable Growth for Cell & Gene Therapies

Krystal Haynes, Senior Director of Business Development, ICS, at Cencora, outlines the challenges facing cell and gene therapy manufacturers as they attempt to move products from clinical development to commercial availability.

Why Do You Exist? The Clarity Paradox in AI Ascent

Why purpose is becoming the most important infrastructure in AI-driven health care technology.

Navigating the EU’s Joint Clinical Assessment

Pathways to success for this key component of Europe’s new HTA regulation, where thinking beyond the purely technical will be critical.